Gayle Jameson, Emanual Petricoin, Jasgit Sachdev, Lance Liotta, David Loesch, Stephen Anthony, Manpreet Chadha, Mariaelena Pierobon, Kimberly Reeder, Monica Fulk, Linda Vocila, Nina Cantafio, Bryant Dunetz, Nicholas Robert
A recent non-randomized pilot study utilizing molecular profiling (MP) of patients’ tumors to find potential targets and select treatments (Von Hoff, et al., 2010), concluded that:
- This MP approach to selecting treatments benefitted 27% of patients (n=66) with a variety of solid tumor types (95% CI 17-38%) p=0.007, who had disease progression on all prior therapies.
- Clinical benefit was defined by a Growth Modulation Index (GMI) of ≥ 1.3 which calculated the patient’s PFS ratio (PFS on MP selected therapy/PFS on prior therapy).
- 44% (8 of 18) patients with metastatic breast cancer demonstrated longer PFS on an MP suggested regimen compared with the most recent prior regimen on which the patient had experienced PD, (GMI of ≥ 1.3).